22.02.2023, Author: Nico Popp

Stock news: Defence Therapeutics - Big step towards FDA approval — Partnership with world-class cancer clinic City of Hope

  • Biotech
  • cancer treatment
  • mRNA

The renowned City of Hope Clinic in the greater Los Angeles area wants nothing less than to lead the revolution in the fight against cancer. Here, where globally acclaimed breakthroughs against blood cancer and diabetes were achieved in the 1970s, the biotech company Defence Therapeutics now wants to clear important hurdles in the approval process of the US Food and Drug Administration (FDA). Here is what the collaboration is all about and what it could mean for the young biotech company.

Time to read: 5 minutes

The Canadian biotech company Defence Therapeutics has moved closer to its goal of bringing several projects in the fight against cancer into clinical trials in 2023. Around the AccuTOX™ chemotherapy project, the Company announced a collaboration with the renowned City of Hope National Medical Center in Duarte in the Los Angeles area. The clinic is considered one of the best cancer clinics in the US and worldwide. The affiliated Beckman Research Institute was founded in 1951 and is synonymous with medical breakthroughs in cancer, HIV and diabetes that directly benefit patients, true to the motto of translational research "from bench to bedside".

"From bench to bedside" - research and therapy are traditionally closely intertwined at the renowned City of Hope Hospital. (Photo: City of Hope)

City of Hope: "World leader in clinical trials."

Measured by citations, the Beckman Research Institute ranks 481 out of 20331 universities worldwide. Citations are like a kind of currency within the scientific community and indicate how relevant a research contribution is. The Beckman Research Institute and the affiliated City of Hope National Medical Center are now helping Defence Therapeutics advance its AccuTOX™ compound to regulatory approval. The experienced scientists prepare all applications for a Phase I study, take care of study design and review all preliminary work already done by Defence Therapeutics in order to be able to initiate a Phase I study with AccuTOX™ as soon as possible.

Approximately 50 applications to the FDA

submitted by City of Hope Hospital annually.

"This is an important milestone, and we are very confident that City of Hope will support us in this FDA process to approve the initiation of a Phase I clinical trial in the US. With AccuTOX™ potentially entering clinical trials in the US later this year, Defence expects to be able to use AccuTOX™ for the treatment of various cancer tumors," said Sébastien Plouffe, CEO and President of Defence. The City of Hope National Medical Center and affiliated research facilities implement approximately 400 clinical trials involving over 6,000 patients annually and consider themselves "world leaders in the conduct of clinical trials." For the progress of Defence Therapeutics and its chemotherapy project AccuTOX™, the university hospital should be the perfect partner - in addition to preparing the registration documents, the hospital could also conduct the Phase I trial in the next step - experience around cancer studies as well as suitable patients are sufficiently available at the City of Hope, which invested around USD 1 billion in a "Cancer Campus" as recently as 2019.

Research and cure - City of Hope stands for about 400 clinical studies with over 6,000 patients annually. (photo: City of Hope)

AccuTOX™ as one project among many

Also, partnering with such a renowned university hospital should ensure that Defence Therapeutics' projects are even more widely recognized within the scientific community. Defence Therapeutics' other projects, such as mRNA vaccines against various forms of cancer, Accum™ as an ADC drug booster or the planned protein-based vaccine against HPV - a successful Phase I trial application should provide a tailwind for all of its projects. More recently, Defence Therapeutics partnered with the University of Montréal and the Lady Davis Institute of the Jewish General Hospital to launch a new vaccine platform sponsored by Canadian biotech catalyst CQDM, whose oversight boards include representatives from academia and pharmaceutical companies. The now-announced collaboration with the City of Hope Medical Center, the seventh-best cancer hospital in the US, is thus already the second high-profile cooperation with a renowned research institution within a few weeks.

At the same time, Defence Therapeutics is presenting itself to investors and presenting its comprehensive portfolio to interested representatives from the business world. At the beginning of February, the Company presented at Immuno-Oncology 360° in New York and a little later online at the 6th International Investment Forum (IIF). The presentation by Head of Research Prof. Dr Moutih Rafei is available online and provides an overview of the Company's activities in just a few minutes.


Chart technical situation

Technically, the shares of Defence Therapeutics continue to be on the upswing. After a dynamic price rally in January, the stock entered a consolidation movement but is holding exceedingly stable at the current level. In view of the takeover fantasy noted by several analysts in the biotech sector, as well as the numerous projects that Defence Therapeutics intends to advance in parallel in 2023, the share is always good for building up new momentum. Even the previous all-time high of CAD 8.15 is within the realm of possibility - provided operational progress is made. The most recent lows offer themselves as hedging opportunities.

Healthy consolidation - is the share now gaining new momentum? (source: Refinitiv Eikon, as of 2/21/2023)

Interim conclusion: Strong partners for strong projects

The now-announced collaboration of Defence Therapeutics with the City of Hope National Medical Center underlines the ambitions of the versatile biotech from Canada. The researchers from the greater Los Angeles area oversee numerous studies around active substances against cancer every year and bring everything they need to have a Phase I study approved by the regulatory authority FDA. The reputation of the university hospital and the associated Beckman Research Institute also increases the visibility of all other Defence Therapeutics projects and, at the same time, reduces the risk of procedural errors, which can never be completely ruled out in complex approval processes.

The shares of Defence Therapeutics have come to rest after their dynamic rise in January - the overall chart picture nevertheless remains promising. Given Defence Therapeutics' operational progress and its bulging and synergistic pipeline thanks to its platform approach, investors can expect a continuous news flow. According to management, the Company has received positive feedback during recent investor events. The stock remains an exciting alternative in the biotech sector, which is currently in high demand.

The update is based on the initial report 12/2021

Conflict of interest

Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.

In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is also a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

Risk notice

Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.